Multivariable disease-free survival and overall survival analysis of total population (n=365)
Disease-free survival | Overall survival | |||||
HR | 95% CI | P value | HR | 95% CI | P value | |
Age (years) | ||||||
≤60 >60 | 1.00 0.98 | Ref (0.78 to 1.23) | 0.852 | 1.00 1.10 | Ref (0.84 to 1.45) | 0.489 |
FIGO stage | ||||||
IIIC IV | 1.00 1.25 | Ref (0.96 to 1.64) | 0.100 | 1.00 1.15 | Ref (0.82 to 1.62) | 0.413 |
Cycles of NACT | ||||||
3–4 6 | 1.00 1.09 | Ref (0.85 to 1.38) | 0.498 | 1.00 1.24 | Ref (0.93 to 1.65) | 0.145 |
PCI | ||||||
≤10 >10 | 1.00 1.25 | Ref (0.96 to 1.64) | 0.098 | 1.00 1.10 | Ref (0.80 to 1.51) | 0.542 |
Aletti score | ||||||
<8 ≥8 | 1.00 1.18 | Ref (0.91 to 1.54) | 0.209 | 1.00 1.20 | Ref (0.88 to 1.64) | 0.248 |
CC-score | ||||||
CC-0 CC-1 | 1.00 1.16 | Ref (0.84 to 1.61) | 0.362 | 1.00 1.07 | Ref (0.73 to 1.58) | 0.726 |
CRS | ||||||
CRS 1–2 CRS 3 | 1.00 0.53 | Ref (0.39 to 0.71) | <0.001 | 1.00 0.42 | Ref (0.28 to 0.63) | <0.001 |
CC, complete cytoreduction; CRS, chemotherapy response score; FIGO, International Federation of Gynecology and Obstetrics; NACT, neoadjuvant chemotherapy; PCI, peritoneal cancer index; Ref, reference.